Detalles de la búsqueda
1.
Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
Breast Cancer Res
; 16(3): R62, 2014 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-24919951
2.
Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion.
Nat Commun
; 10(1): 3505, 2019 Aug 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31388012
3.
Activation of Farnesoid X Receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts.
Cancer Lett
; 437: 89-99, 2018 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30176263
4.
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.
Nat Genet
; 49(3): 444-450, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28112739
5.
Identification of novel 2-(1H-indol-1-yl)-benzohydrazides CXCR4 ligands impairing breast cancer growth and motility.
Future Med Chem
; 8(2): 93-106, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26807787
6.
Activated FXR Inhibits Leptin Signaling and Counteracts Tumor-promoting Activities of Cancer-Associated Fibroblasts in Breast Malignancy.
Sci Rep
; 6: 21782, 2016 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26899873
7.
Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion.
Nat Commun
; 6: 10044, 2015 Nov 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-26610607
8.
Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.
Nat Genet
; 49(6): 970, 2017 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-28546573
Resultados
1 -
8
de 8
1
Próxima >
>>